1.25

1.63% 0.02

Pre-market: 1.24 -0.01 -0.80%

Medicinova Inc (MNOV)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Medicinova Inc stock is traded at $1.25, with a volume of 122.08K. It is up +1.63% in the last 24 hours and down -9.42% over the past month. MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.

Previous Close:

$1.23

Open:

$1.27

24h Volume:

122.08K

Relative Volume:

3.29

Market Cap:

$61.53M

Revenue:

$409.70K

Net Income/Loss:

$-12.00M

P/E Ratio:

-5.1125

EPS:

-0.2445

Net Cash Flow:

$-9.81M

1W Performance:

-3.85%

1M Performance:

-9.42%

6M Performance:

-17.76%

1Y Performance:

-6.02%

1-Day Range:

$1.22

$1.28

1-Week Range:

$1.22

$1.30

52-Week Range:

$1.168

$1.96

Medicinova Inc Stock (MNOV) Company Profile

Name

Medicinova Inc

Sector

Healthcare (1104)

Industry

Biotechnology (621)

Phone

858-373-1500

Address

4275 EXECUTIVE SQUARE, LA JOLLA, CA

Employee

Twitter

@MedicinovaJapan

Next Earnings Date

2026-05-12

Latest SEC Filings

MNOV's Discussions on Twitter

Compare MNOV vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
MNOV Medicinova Inc	1.25	61.53M	409.70K	-12.00M	-9.81M	-0.2445
VRTX Vertex Pharmaceuticals Inc	450.46	114.33B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	614.98	64.47B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	884.20	54.99B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	287.80	38.42B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	160.06	34.03B	742.00K	-1.37B	-1.07B	-7.0731

Medicinova Inc Stock (MNOV) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-16-26	Initiated	H.C. Wainwright	Buy
Mar-10-21	Initiated	Maxim Group	Buy
Mar-25-19	Resumed	B. Riley FBR	Buy
Mar-28-18	Initiated	B. Riley FBR, Inc.	Buy
Apr-18-17	Initiated	Credit Suisse	Outperform
Jan-04-13	Reiterated	Ladenburg Thalmann	Buy
May-24-12	Downgrade	MLV & Co	Buy → Hold
Oct-18-11	Reiterated	MLV Capital	Buy
Jun-22-11	Initiated	Global Hunter Securities	Buy
May-12-10	Initiated	Wedbush	Outperform
Nov-12-08	Reiterated	Ladenburg Thalmann	Buy
May-15-08	Initiated	Rodman & Renshaw	Mkt Outperform
Jul-09-07	Initiated	Punk, Ziegel & Co	Buy

View All

Medicinova Inc Stock (MNOV) Latest News

Jun 08, 2026

Alcohol Use Disorder Market Set to Expand at a 12.1% CAGR During the Forecast Period (2026–2036), Owing to the Emergence of Novel Mechanisms Such as 5-HT3 Pathway, NOP Receptor, mGluR5 NAM, and Other | DelveInsight - GlobeNewswire Inc.

Jun 08, 2026

MediciNova receives U.S. patent allowance for ibudilast combo By Investing.com - Investing.com South Africa

Jun 08, 2026

MediciNova receives U.S. patent allowance for ibudilast combo - Investing.com

Jun 08, 2026

Patent clears path for MediciNova MN-166 combo in glioblastoma - Stock Titan

Jun 08, 2026

Jun 07, 2026